# Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

> **NCT02178722** · PHASE1,PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 444 (actual)

## Conditions studied

- Microsatellite-instability (MSI) High Colorectal Cancer (CRC)
- Endometrial Cancer
- Head and Neck Cancer
- Hepatocellular Carcinoma (HCC)
- Gastric Cancer
- Lung Cancer
- Lymphoma
- Renal Cell Carcinoma (RCC)
- Ovarian Cancer
- Solid Tumors
- UC (Urothelial Cancer)
- Melanoma
- Bladder Cancer
- Triple Negative Breast Cancer (TNBC)

## Interventions

- **DRUG:** MK-3475
- **DRUG:** INCB024360

## Key facts

- **NCT ID:** NCT02178722
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-17
- **Primary completion:** 2018-11-26
- **Final completion:** 2020-11-06
- **Target enrollment:** 444 (ACTUAL)
- **Last updated:** 2022-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02178722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02178722, "Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02178722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*